Literature DB >> 11586351

Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

G G Levy1, W C Nichols, E C Lian, T Foroud, J N McClintick, B M McGee, A Y Yang, D R Siemieniak, K R Stark, R Gruppo, R Sarode, S B Shurin, V Chandrasekaran, S P Stabler, H Sabio, E E Bouhassira, J D Upshaw, D Ginsburg, H M Tsai.   

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a life-threatening systemic illness of abrupt onset and unknown cause. Proteolysis of the blood-clotting protein von Willebrand factor (VWF) observed in normal plasma is decreased in TTP patients. However, the identity of the responsible protease and its role in the pathophysiology of TTP remain unknown. We performed genome-wide linkage analysis in four pedigrees of humans with congenital TTP and mapped the responsible genetic locus to chromosome 9q34. A predicted gene in the identified interval corresponds to a segment of a much larger transcript, identifying a new member of the ADAMTS family of zinc metalloproteinase genes (ADAMTS13). Analysis of patients' genomic DNA identified 12 mutations in the ADAMTS13 gene, accounting for 14 of the 15 disease alleles studied. We show that deficiency of ADAMTS13 is the molecular mechanism responsible for TTP, and suggest that physiologic proteolysis of VWF and/or other ADAMTS13 substrates is required for normal vascular homeostasis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11586351     DOI: 10.1038/35097008

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  391 in total

Review 1.  Extracellular matrix proteins in hemostasis and thrombosis.

Authors:  Wolfgang Bergmeier; Richard O Hynes
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-02-01       Impact factor: 10.005

2.  A new name in thrombosis, ADAMTS13.

Authors:  J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-23       Impact factor: 11.205

3.  Variations in aggrecan structure modulate its susceptibility to aggrecanases.

Authors:  Peter J Roughley; James Barnett; Fengrong Zuo; John S Mort
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

4.  Genetic variations in the ADAMTS12 gene are associated with schizophrenia in Puerto Rican patients of Spanish descent.

Authors:  Irina N Bespalova; Gary W Angelo; Ben P Ritter; Jason Hunter; Maria L Reyes-Rabanillo; Larry J Siever; Jeremy M Silverman
Journal:  Neuromolecular Med       Date:  2012-02-10       Impact factor: 3.843

5.  A model for single-substrate trimolecular enzymatic kinetics.

Authors:  Wei Chen; Cheng Zhu
Journal:  Biophys J       Date:  2010-05-19       Impact factor: 4.033

6.  Multiple domains of ADAMTS13 are targeted by autoantibodies against ADAMTS13 in patients with acquired idiopathic thrombotic thrombocytopenic purpura.

Authors:  X Long Zheng; Haifeng M Wu; Dezhi Shang; Erica Falls; Christopher G Skipwith; Spero R Cataland; Charles L Bennett; Hau C Kwaan
Journal:  Haematologica       Date:  2010-04-07       Impact factor: 9.941

Review 7.  Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases.

Authors:  Takayuki Shiomi; Vincent Lemaître; Jeanine D'Armiento; Yasunori Okada
Journal:  Pathol Int       Date:  2010-07       Impact factor: 2.534

8.  ADAMTS-7: a metalloproteinase that directly binds to and degrades cartilage oligomeric matrix protein.

Authors:  Chuan-Ju Liu; Wei Kong; Kiril Ilalov; Shuang Yu; Ke Xu; Lisa Prazak; Marc Fajardo; Bantoo Sehgal; Paul E Di Cesare
Journal:  FASEB J       Date:  2006-04-03       Impact factor: 5.191

Review 9.  Biological functions of fucose in mammals.

Authors:  Michael Schneider; Esam Al-Shareffi; Robert S Haltiwanger
Journal:  Glycobiology       Date:  2017-07-01       Impact factor: 4.313

Review 10.  ADAMTS13: more than a regulator of thrombosis.

Authors:  Yun Feng; Xueyin Li; Juan Xiao; Wei Li; Jing Liu; Xue Zeng; Xi Chen; Suhua Chen
Journal:  Int J Hematol       Date:  2016-10-01       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.